argenx
ARGX.BRHealthcare · Biotechnology · NL729.80EUR+0.30%
StratDeckargenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Price · Past year
Loading chart…
Checks
- Pass: Price trending up The figures
- Pass: Sales growing faster than its peers The figures
- Pass: More profitable than similar companies The figures
- Pass: Analysts rate it a buy The figures
- Fail: Costs more than similar companies The figures
- Pass: Beat profit forecasts The figures
Share
Keep researching
Where next from ARGX.BR
Other stocks you may like
Fundamentals
Yahoo FinanceShowHide
What's happening?
ARGX.BR is lagging Healthcare this month The figures
- 1D
- +0.30%
- 7D
- -0.46%
- 1M
- -16.25%
- 3M
- -3.16%
- 6M
- +3.14%
- YTD
- +1.81%
What is the market expecting?
StratDeckCosts more than similar companies, and analysts expect the price to rise The figures
Value score vs Healthcare peers
25- Fwd P/E23.322
- P/B6.529
- P/E34.727
- Rev growth+59.3%98
Not scored on Yield. The rest were reweighted to make up the difference.
Is the business delivering?
Sales are growing faster than at similar companies, and profit per share is up The figures
Earnings by quarter
Latest quarter 472M · +106M on the quarter before · +227M on a year earlier
- 245MJul25—
- 344MOct25+98.9M
- 533MFeb26+189M
- 366MMay26-167M
- 472MJul26+106M
Yahoo serves only the most recent statements; EPS goes back further.
How does it compare?
Nearest in Healthcare on valueStratDeckARGX.BR is worse value than most Healthcare stocks The figures
What happens next?
Reports next on 22 Oct, tomorrow
Daily market updates
Get the brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday, Wednesday and Friday email.